Neurosteroid 3α-androstanediol efficiently counteracts paclitaxel-induced peripheral neuropathy and painful symptoms

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Meyer, Laurence ^a   Patte Mensah, Christine ^a   Taleb, Omar ^a   Mensah Nyagan, Ayikoe Guy ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANEDIOL; ANTINEOPLASTIC AGENT; NEUROPROTECTIVE AGENT; PACLITAXEL;

ACTION POTENTIAL; ANALOGS AND DERIVATIVES; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; HYPERALGESIA; MALE; NERVE CONDUCTION; NERVE FIBER; NEURALGIA; PAIN; PAIN MEASUREMENT; PATHOLOGY; PATHOPHYSIOLOGY; PERIPHERAL NERVE; PERIPHERAL NERVOUS SYSTEM DISEASES; RAT; SPRAGUE DAWLEY RAT;

ACTION POTENTIALS; ANDROSTANE-3,17-DIOL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; HYPERALGESIA; MALE; NERVE FIBERS; NEURAL CONDUCTION; NEURALGIA; NEUROPROTECTIVE AGENTS; PACLITAXEL; PAIN; PAIN MEASUREMENT; PERIPHERAL NERVES; PERIPHERAL NERVOUS SYSTEM DISEASES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84894173275     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080915     Document Type: Article

References (78)

1. Balayssac D, Ferrier J, Descoeur J, Ling B, Pezet D, Eschalier A, Authier N (2011) Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence. Expert Opin Drug Saf 10: 407-417. doi:10.1517/14740338. 2011.543417. PubMed: 21210753.
2. Quasthoff S, Hartung HP (2002) Chemotherapy-induced peripheral neuropathy. J Neurol 249: 9-17. doi:10.1007/PL00007853. PubMed: 11954874. (Pubitemid 34119018)
3. Authier N, Balayssac D, Marchand F, Ling B, Zangarelli A, Descoeur J, Coudore F, Bourinet E, Eschalier A (2009) Animal models of chemotherapy-evoked painful peripheral neuropathies. Neurotherapeutics 6: 620-629. doi:10.1016/j.nurt.2009.07.003. PubMed: 19789067.
4. Dougherty PM, Cata JP, Cordella JV, Burton A, Weng HR (2004) Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain 109: 132-142. doi:10.1016/j.pain.2004.01.021. PubMed: 15082135. (Pubitemid 38479779)
5. Verstappen CC, Heimans JJ, Hoekman K, Postma TJ (2003) Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 63: 1549-1563. doi: 10.2165/00003495-200363150-00003. PubMed: 12887262. (Pubitemid 36976138)
6. Cai J, Zheng T, Masood R, Smith DL, Hinton DR, Kim CN, Fang G, Bhalla K, Gill PS (2000) Paclitaxel Induces Apoptosis in AIDS-Related Kaposi's Sarcoma Cells. Sarcoma 4: 37-45. doi:10.1155/S1357714X00000074. PubMed: 18521433. (Pubitemid 30480280)
7. Croom KF, Dhillon S (2011) Bevacizumab: a review of its use in combination with paclitaxel or capecitabine as first-line therapy for HER2-negative metastatic breast cancer. Drugs 71: 2213-2229. doi: 10.2165/11207720-000000000-00000. PubMed: 22035518.
8. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN (1991) Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83: 1797-1805. doi:10.1093/jnci/83.24.1797. PubMed: 1683908.
9. Le XF, Bast RC Jr. (2011) Src family kinases and paclitaxel sensitivity. Cancer Biol Ther 12: 260-269. doi:10.4161/cbt.12.4.16430. PubMed: 21646863.
10. Singh S, Dash AK (2009) Paclitaxel in cancer treatment: perspectives and prospects of its delivery challenges. Crit Rev Ther Drug Carrier Syst 26: 333-372. doi:10.1615/CritRevTherDrugCarrierSyst.v26.i4.10. PubMed: 20001890.
11. Young M, Plosker GL (2001) Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer. Pharmacoeconomics 19: 1227-1259. doi:10.2165/00019053-200119120-00005. PubMed: 11772158. (Pubitemid 34074786)
12. Cavaletti G, Bogliun G, Marzorati L, Zincone A, Marzola M, Colombo N, Tredici G (1995) Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer 75: 1141-1150. doi: 10.1002/1097-0142(19950301) 75:5. PubMed: 7850713.
13. Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR (1994) Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol 35: 304-311. doi:10.1002/ana.410350310. PubMed: 7907208. (Pubitemid 24089653)
14. Forsyth PA, Balmaceda C, Peterson K, Seidman AD, Brasher P, DeAngelis LM (1997) Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J Neuro Oncol 35: 47-53. doi:10.1023/A: 1005805907311. PubMed: 9266440. (Pubitemid 27361845)
15. Gordon AN, Stringer CA, Matthews CM, Willis DL, Nemunaitis J (1997) Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is doselimiting. J Clin Oncol 15: 1965-1973. PubMed: 9164208. (Pubitemid 27209527)
16. Polomano RC, Mannes AJ, Clark US, Bennett GJ (2001) A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain 94: 293-304. doi:10.1016/S0304-3959(01)00363-3. PubMed: 11731066. (Pubitemid 33145399)
17. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC (1993) Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20: 1-15. PubMed: 8102012. (Pubitemid 23239390)
18. van den Bent MJ, van Raaij-van den Aarssen VJ, Verweij J, Doorn PA, Smitt Sillevis (1997) Progression of paclitaxel-induced neuropathy following discontinuation of treatment. Muscle Nerve 20: 750-752. doi: 10.1002/(SICI)1097-4598(199706)20:6. PubMed: 9149085. (Pubitemid 27197731)
19. Durand JP, Alexandre J, Guillevin L, Goldwasser F (2005) Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy. Anti Cancer Drugs 16: 587-591. doi: 10.1097/00001813- 200506000-00015. PubMed: 15846125. (Pubitemid 40685744)
20. Gamelin L, Boisdron-Celle M, Delva R, Guérin-Meyer V, Ifrah N, Morel A, Gamelin E (2004) Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 10: 4055-4061. doi: 10.1158/1078-0432.CCR-03-0666. PubMed: 15217938. (Pubitemid 38812481)
21. Lang E, Hord AH, Denson D (1996) Venlafaxine hydrochloride (Effexor) relieves thermal hyperalgesia in rats with an experimental mononeuropathy. Pain 68: 151-155. doi:10.1016/S0304-3959(96)03223-X. PubMed: 9252010. (Pubitemid 126407767)
22. Ling B, Authier N, Balayssac D, Eschalier A, Coudore F (2007) Behavioral and pharmacological description of oxaliplatin-induced painful neuropathy in rat. Pain 128: 225-234. doi:10.1016/j.pain.2006.09.016. PubMed: 17084975. (Pubitemid 46389544)
23. Marchand F, Alloui A, Chapuy E, Jourdan D, Pelissier T, Ardid D, Hernandez A, Eschalier A (2003) Evidence for a monoamine mediated, opioid-independent, antihyperalgesic effect of venlafaxine, a non-tricyclic antidepressant, in a neurogenic pain model in rats. Pain 103: 229-235. doi:10.1016/S0304-3959(03)00168-4. PubMed: 12791429. (Pubitemid 36638812)
24. Meyer L, Patte-Mensah C, Taleb O, Mensah-Nyagan AG (2010) Cellular and functional evidence for a protective action of neurosteroids against vincristine chemotherapy-induced painful neuropathy. Cell Mol Life Sci 67: 3017-3034. doi:10.1007/s00018-010-0372-0. PubMed: 20431905.
25. Meyer L, Patte-Mensah C, Taleb O, Mensah-Nyagan AG (2011) Allopregnanolone prevents and suppresses oxaliplatin-evoked painful neuropathy: multi-parametric assessment and direct evidence. Pain 152: 170-181. doi:10.1016/j.pain.2010.10.015. PubMed: 21071147.
26. Belelli D, Lambert JJ (2005) Neurosteroids: endogenous regulators of the GABA(A) receptor. Nat Rev Neurosci 6: 565-575. doi:10.1038/nrn1703. PubMed: 15959466. (Pubitemid 40942823)
27. Bitran D, Hilvers RJ, Frye CA, Erskine MS (1996) Chronic anabolic-androgenic steroid treatment affects brain GABA(A) receptor-gated chloride ion transport. Life Sci 58: 573-583. doi: 10.1016/0024-3205(95)02326-7. PubMed: 8632710.
28. Frye CA, Duncan JE, Basham M, Erskine MS (1996) Behavioral effects of 3 alpha-androstanediol. II: Hypothalamic and preoptic area actions via a GABAergic mechanism. Behav Brain Res 79: 119-130. doi: 10.1016/0166-4328(96)00005-8. PubMed: 8883823. (Pubitemid 26308932)
29. Frye CA, Park D, Tanaka M, Rosellini R, Svare B (2001) The testosterone metabolite and neurosteroid 3alpha-androstanediol may mediate the effects of testosterone on conditioned place preference. Psychoneuroendocrinol 26: 731-750. doi:10.1016/S0306-4530(01)00027-0. PubMed: 1174408411500254. (Pubitemid 32738997)
30. Hosie AM, Wilkins ME, da Silva HM, Smart TG (2006) Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites. Nature 444: 486-489. doi:10.1038/nature05324. PubMed: 17108970. (Pubitemid 44809065)
31. Reddy DS (2008) Mass spectrometric assay and physiological- pharmacological activity of androgenic neurosteroids. Neurochem Int 52: 541-553. doi:10.1016/j.neuint.2007.05.019. PubMed: 17624627.
32. Frye CA, Babson A, Walf AA (2007) Self-administration of 3alpha-androstanediol increases locomotion and analgesia and decreases aggressive behavior of male hamsters. Pharmacol Biochem Behav 86: 415-421. doi:10.1016/j.pbb.2006.05.025. PubMed: 16828856. (Pubitemid 46282039)
33. Rhodes ME, Frye CA (2004) Androgens in the hippocampus can alter, and be altered by, ictal activity. Pharmacol Biochem Behav 78: 483-493. doi:10.1016/j.pbb.2004.04.020. PubMed: 15251257. (Pubitemid 38901016)
34. Edinger KL, Frye CA (2004) Testosterone's analgesic, anxiolytic, and cognitive-enhancing effects may be due in part to actions of its 5alpha-reduced metabolites in the hippocampus. Behav Neurosci 118: 1352-1364. doi:10.1037/0735-7044.118.6.1352. PubMed: 15598144. (Pubitemid 39578482)
35. Akwa Y, Purdy RH, Koob GF, Britton KT (1999) The amygdala mediates the anxiolytic-like effect of the neurosteroid allopregnanolone in rat. Behav Brain Res 106: 119-125. doi:10.1016/S0166-4328(99)00101-1. PubMed: 10595427. (Pubitemid 29528492)
36. Ciriza I, Azcoitia I, Garcia-Segura LM (2004) Reduced progesterone metabolites protect rat hippocampal neurones from kainic acid excitotoxicity in vivo. J Neuroendocrinol 16: 58-63. doi:10.1111/j.1365-2826.2004.01121.x. PubMed: 14962077. (Pubitemid 38159394)
37. Ciriza I, Carrero P, Frye CA, Garcia-Segura LM (2006) Reduced metabolites mediate neuroprotective effects of progesterone in the adult rat hippocampus. The synthetic progestin medroxyprogesterone acetate (Provera) is not neuroprotective. J Neurobiol 66: 916-928. doi: 10.1002/neu.20293. PubMed: 16758493. (Pubitemid 44222653)
38. Griffin LD, Gong W, Verot L, Mellon SH (2004) Niemann-Pick type C disease involves disrupted neurosteroidogenesis and responds to allopregnanolone. Nat Med 10: 704-711. doi:10.1038/nm1073. PubMed: 15208706. (Pubitemid 38937635)
39. Meyer L, Venard C, Schaeffer V, Patte-Mensah C, Mensah-Nyagan AG (2008) The biological activity of 3alpha-hydroxysteroid oxido-reductase in the spinal cord regulates thermal and mechanical pain thresholds after sciatic nerve injury. Neurobiol Dis 30: 30-41. doi:10.1016/j.nbd.2007.12.001. PubMed: 18291663. (Pubitemid 351391981)
40. Patte-Mensah C, Kibaly C, Boudard D, Schaeffer V, Béglé A, Saredi S, Meyer L, Mensah-Nyagan AG (2006) Neurogenic pain and steroid synthesis in the spinal cord. J Mol Neurosci 28: 17-31. doi:10.1385/JMN:28:1:17. PubMed: 16632873.
41. Uzunova V, Sheline Y, Davis JM, Rasmusson A, Uzunov DP, Costa E, Guidotti A (1998) Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci U S A 95: 3239-3244. doi:10.1073/pnas.95.6.3239. PubMed: 9501247. (Pubitemid 28135886)
42. Wang JM, Singh C, Liu L, Irwin RW, Chen S, Chung EJ, Thompson RF, Brinton RD (2010) Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 107: 6498-6503. doi:10.1073/pnas.1001422107. PubMed: 20231471.
43. Lappe-Siefke C, Goebbels S, Gravel M, Nicksch E, Lee J, Braun PE, Griffiths IR, Nave KA (2003) Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination. Nat Genet 33: 366-374. doi:10.1038/ng1095. PubMed: 12590258. (Pubitemid 36278853)
44. LeBlanc AC, Pringle J, Lemieux J, Poduslo JF, Mezei C (1992) Regulation of 2',3'-cyclic nucleotide phosphodiesterase gene expression in experimental peripheral neuropathies. Brain Res. Mol Brain Res 15: 40-46. doi:10.1016/0169-328X(92)90149-6. PubMed: 1279349.
45. Baulieu EE, Robel P, Schumacher M (1999) Contemporary Endocrinology. Totowa: Humana Press. 378 pp.
46. Melcangi RC, Garcia-Segura LM, Mensah-Nyagan AG (2008) Neuroactive steroids: state of the art and new perspectives. Cell Mol Life Sci 65: 777-797. doi:10.1007/s00018-007-7403-5. PubMed: 18038216.
47. Mensah-Nyagan AG, Do-Rego JL, Beaujean D, Luu-The V, Pelletier G, Vaudry H (1999) Neurosteroids: expression of steroidogenic enzymes and regulation of steroid biosynthesis in the central nervous system. Pharmacol Rev 51: 63-81. PubMed: 10049998. (Pubitemid 29113866)
48. Zimmermann M (1983) Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16: 109-110. doi: 10.1016/0304-3959(83)90201-4. PubMed: 6877845.
49. Hargreaves K, Dubner R, Brown F, Flores C, Joris J (1988) A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32: 77-88. doi:10.1016/0304-3959(88)90026-7. PubMed: 3340425.
50. Lauria G, Lombardi R, Borgna M, Penza P, Bianchi R, Savino C, Canta A, Nicolini G, Marmiroli P, Cavaletti G (2005) Intraepidermal nerve fiber density in rat foot pad: neuropathologic-neurophysiologic correlation. J Peripher Nerv Syst 10: 202-208. doi:10.1111/j.1085-9489.2005.0010210.x. PubMed: 15958131. (Pubitemid 40984894)
51. Shaw G, Osborn M, Weber K (1986) Reactivity of a panel of neurofilament antibodies on phosphorylated and dephosphorylated neurofilaments. Eur J Cell Biol 42: 1-9. PubMed: 3539605.
52. Siau C, Xiao W, Bennett GJ (2006) Paclitaxel- and vincristine-evoked painful peripheral neuropathies: loss of epidermal innervation and activation of Langerhans cells. Exp Neurol 201: 507-514. doi:10.1016/j.expneurol.2006.05.007. PubMed: 16797537. (Pubitemid 44344243)
53. Sprinkle TJ (1989) 2',3'-cyclic nucleotide 3'-phosphodiesterase, an oligodendrocyte-Schwann cell and myelin-associated enzyme of the nervous system. Crit Rev Neurobiol 4: 235-301. PubMed: 2537684.
54. Yoshino JE, Dinneen MP, Sprinkle TJ, DeVries GH (1985) Localization of 2',3'-cyclic nucleotide 3'-phosphodiesterase on cultured Schwann cells. Brain Res 325: 199-203. doi:10.1016/0006-8993(85)90316-6. PubMed: 2983827. (Pubitemid 15134882)
55. Lee MK, Cleveland DW (1996) Neuronal intermediate filaments. Annu Rev Neurosci 19: 187-217. doi:10.1146/annurev.ne.19.030196.001155. PubMed: 8833441. (Pubitemid 26080827)
56. Frye CA, Walf AA (2009) Depression-like behavior of aged male and female mice is ameliorated with administration of testosterone or its metabolites. Physiol Behav 97: 266-269. doi:10.1016/j.physbeh.2009.02.022. PubMed: 19254734.
57. Frye CA, Edinger KL, Lephart ED, Walf AA (2010) 3alpha-androstanediol, but not testosterone, attenuates age-related decrements in cognitive, anxiety, and depressive behavior of male rats. Front Aging Neurosci 2: 15. PubMed: 20552051.
58. Roglio I, Bianchi R, Camozzi F, Carozzi V, Cervellini I, Crippa D, Lauria G, Cavaletti G, Melcangi RC (2009) Docetaxel-induced peripheral neuropathy: protective effects of dihydroprogesterone and progesterone in an experimental model. J Peripher Nerv Syst 14: 347-355.
59. Postma TJ, Vermorken JB, Liefting AJ, Pinedo HM, Heimans JJ (1995) Paclitaxel-induced neuropathy. Ann Oncol 6: 489-494. PubMed: 7669713.
60. Cavaletti G, Tredici G, Braga M, Tazzari S (1995) Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of taxol. Exp Neurol 133: 64-72. doi:10.1006/exnr.1995.1008. PubMed: 7601264.
61. Wang MS, Davis AA, Culver DG, Glass JD (2002) WldS mice are resistant to paclitaxel (taxol) neuropathy. Ann Neurol 52: 442-447. doi: 10.1002/ana.10300. PubMed: 12325073.
62. Fazio R, Quattrini A, Bolognesi A, Bordogna G, Villa E, Previtali S, Canal N, Nemni R (1999) Docetaxel neuropathy: a distal axonopathy. Acta Neuropathol (Berl) 98: 651-653. doi:10.1007/s004010051132. PubMed: 10603043.
63. Boyette-Davis J, Xin W, Zhang H, Dougherty PM (2011) Intraepidermal nerve fiber loss corresponds to the development of taxol-induced hyperalgesia and can be prevented by treatment with minocycline. Pain 152: 308-313. doi:10.1016/j.pain.2010.10.030. PubMed: 21145656.
64. Dougherty PM, Cata JP, Burton AW, Vu K, Weng HR (2007) Dysfunction in multiple primary afferent fiber subtypes revealed by quantitative sensory testing in patients with chronic vincristine-induced pain. J Pain Symptom Manage 33: 166-179. doi:10.1016/j.jpainsymman.2006.08.006. PubMed: 17280922. (Pubitemid 46186866)
65. Tanner KD, Reichling DB, Levine JD (1998) Nociceptor hyper-responsiveness during vincristine-induced painful peripheral neuropathy in the rat. J Neurosci 18: 6480-6491. PubMed: 9698336.
66. Cliffer KD, Siuciak JA, Carson SR, Radley HE, Park JS, Lewis DR, Zlotchenko E, Nguyen T, Garcia K, Tonra JR, Stambler N, Cedarbaum JM, Bodine SC, Lindsay RM, DiStefano PS (1998) Physiological characterization of taxol-induced large-fiber sensory neuropathy in the rat. Ann Neurol 43: 46-55. doi:10.1002/ana.410430111. PubMed: 9450768. (Pubitemid 28124648)
67. Kriz J, Zhu Q, Julien JP, Padjen AL (2000) Electrophysiological properties of axons in mice lacking neurofilament subunit genes: disparity between conduction velocity and axon diameter in absence of NF-H. Brain Res 885: 32-44. doi:10.1016/S0006-8993(00)02899-7. PubMed: 11121527.
68. Hoffman PN, Cleveland DW, Griffin JW, Landes PW, Cowan NJ, Price DL (1987) Neurofilament gene expression: a major determinant of axonal caliber. Proc Natl Acad Sci U S A 84: 3472-3476. doi:10.1073/pnas.84.10.3472. PubMed: 3472217. (Pubitemid 17085426)
69. Hoffman PN, Griffin JW, Gold BG, Price DL (1985) Slowing of neurofilament transport and the radial growth of developing nerve fibers. J Neurosci 5: 2920-2929. PubMed: 2414416. (Pubitemid 16225492)
70. Hoffman PN, Griffin JW, Price DL (1984) Control of axonal caliber by neurofilament transport. J Cell Biol 99: 705-714. doi:10.1083/jcb.99.2.705. PubMed: 6204997. (Pubitemid 14065199)
71. Amato SF, Swart JM, Berg M, Wanebo HJ, Mehta SR, Chiles TC (1998) Transient stimulation of the c-Jun-NH2-terminal kinase/activator protein 1 pathway and inhibition of extracellular signal-regulated kinase are early effects in paclitaxel-mediated apoptosis in human B lymphoblasts. Cancer Res 58: 241-247. PubMed: 9443400. (Pubitemid 28047062)
72. Yang JY, Hung MC (2011) Deciphering the role of forkhead transcription factors in cancer therapy. Curr Drug Targets 12: 1284-1290. doi:10.2174/ 138945011796150299. PubMed: 21443462.
73. Peters CM, Jimenez-Andrade JM, Kuskowski MA, Ghilardi JR, Mantyh PW (2007) An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat. Brain Res 1168: 46-59. doi:10.1016/j.brainres.2007.06.066. PubMed: 17698044. (Pubitemid 47320623)
74. Patte-Mensah C, Kibaly C, Mensah-Nyagan AG (2005) Substance P inhibits progesterone conversion to neuroactive metabolites in spinal sensory circuit: a potential component of nociception. Proc Natl Acad Sci U S A 102: 9044-9049. doi:10.1073/pnas.0502968102. PubMed: 15951421. (Pubitemid 40881075)
75. Patte-Mensah C, Penning TM, Mensah-Nyagan AG (2004) Anatomical and cellular localization of neuroactive 5 alpha/3 alpha-reduced steroid-synthesizing enzymes in the spinal cord. J Comp Neurol 477: 286-299. doi:10.1002/cne.20251. PubMed: 15305365. (Pubitemid 39136235)
76. Edinger KL, Frye CA (2005) Testosterone's anti-anxiety and analgesic effects may be due in part to actions of its 5alpha-reduced metabolites in the hippocampus. Psychoneuroendocrinol 30: 418-430. doi:10.1016/j.psyneuen.2004.11. 001. PubMed: 15721054. (Pubitemid 40249808)
77. Brooks BP, Merry DE, Paulson HL, Lieberman AP, Kolson DL, Fischbeck KH (1998) A cell culture model for androgen effects in motor neurons. J Neurochem 70: 1054-1060. PubMed: 9489725. (Pubitemid 28113638)
78. Cerghet M, Skoff RP, Bessert D, Zhang Z, Mullins C, Ghandour MS (2006) Proliferation and death of oligodendrocytes and myelin proteins are differentially regulated in male and female rodents. J Neurosci 26: 1439-1447. doi:10.1523/JNEUROSCI.2219-05.2006. PubMed: 16452667. (Pubitemid 43237014)